According to Actinium Pharmaceuticals's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3603.44. At the end of 2023 the company had a P/S ratio of > 1000.
Year | P/S ratio | Change |
---|---|---|
2023 | > 1000 | 552.49% |
2022 | 263 | 126.5% |
2021 | 116 | |
2020 | N/A | |
2019 | N/A | |
2018 | N/A | |
2017 | N/A | |
2016 | N/A | |
2015 | N/A | |
2014 | N/A | |
2013 | N/A | |
2012 | N/A | |
2011 | N/A |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Genocea Biosciences
GNCA | 0.0031 | -100.00% | ๐บ๐ธ USA |
Amicus Therapeutics
FOLD | 7.23 | -99.80% | ๐บ๐ธ USA |
BioMarin Pharmaceutical BMRN | 5.92 | -99.84% | ๐บ๐ธ USA |